NEW YORK (GenomeWeb) – San Diego-based diagnostics firm Genalyte today announced it has completed a $44M Series C financing round.
Khosla Ventures joined previous investors Redmile Group, Claremont Creek Ventures, and BioMed Ventures in the round.
Genalyte's CE-marked Maverick Detection System is intended for multiplexed, blood-based, point-of-care diagnostic testing. The firm said in a statement that it can provide results in 15 minutes. The platform is for research use only in the US.